Trial Profile
Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2018
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Acorda Therapeutics
- 09 Nov 2015 Post-hoc subgroup analysis results published in the Clinical Therapeutics
- 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
- 13 Mar 2013 Subgroup analysis presented at the the 65th American Academy of Neurology Annual Meeting (AAN-2013), according to an Acorda Therapeutics media release.